References
- Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518–2528. doi:https://doi.org/10.1056/NEJMoa0902604.
- Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascuar mortality. JAMA 2009;302:412–423.
- Qi Q, Workalemahu T, Zhang C, Hu FB, Qi L. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J 2012;33:325–334. doi:https://doi.org/10.1093/eurheartj/ehr350.
- Paré G, Çaku A, McQueen M, Anand SS, Enas E, Clarke R, Boffa MB, Koschinsky M, Wang X, Yusuf S. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139:1472-1482. doi:https://doi.org/10.1161/CIRCULATIONAHA.118.034311. Clarke R, Koschinsky M, Yusuf S, Boffa MB, Paré G, Caku A, Wang X, Enas E, McQueen M, Anand SS. Lipoprotein(a) levels and the risk of myocardial infarction among seven ethnic groups. Circulation 2019;8.
- Zekavat SM, Ruotsalainen S, Handsaker RE, Alver M, Bloom J, Poterba T, Seed C, Ernst J, Chaffin M, Engreitz J, et al. Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. Nat Commun 2018;9:1–14. doi:https://doi.org/10.1038/s41467-017-02088-w.
- Van Dijk RA, Kolodgie F, Ravandi A, Leibundgut G, Hu PP, Prasad A, Mahmud E, Dennis E, Curtiss LK, Witztum JL, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012;53:2773–2790. doi:https://doi.org/10.1194/jlr.P030890.
- Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol 2019;74:54–66. doi:https://doi.org/10.1016/j.jacc.2019.03.524.
- Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol 2019;16:305–318. doi:https://doi.org/10.1038/s41569-018-0153-2.
- Barre D. The molecular nature and consequences of lipoprotein (A)s association with platelets. Protein Pept Lett 2007;14:839–842. doi:https://doi.org/10.2174/092986607782110202.
- Martínez C, Rivera J, Loyau S, Corral J, González-Conejero R, Lozano ML, Vicente V, Anglés-Cano E. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb Haemost 2001;85:686–693. doi:https://doi.org/10.1055/s-0037-1615654.
- Rand ML, Sangrar W, Hancock MA, Taylor DM, Marcovina SM, Packham MA, Koschinsky ML. Apolipoprotein(a) enhances platelet responses to the thrombin receptor- activating peptide SFLLRN. Arterioscler Thromb Vasc Biol 1998;18:1393–1399. doi:https://doi.org/10.1161/01.ATV.18.9.1393.
- Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 2005;46:1820–1826. doi:https://doi.org/10.1016/j.jacc.2005.07.041.
- Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention. Is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657–666. doi:https://doi.org/10.1016/j.jacc.2006.10.050.
- Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ, Cho P, Sell J, Fan J, Antonino MJ, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding rela. Circ Cardiovasc Interv 2012;5:261–269. doi:https://doi.org/10.1161/CIRCINTERVENTIONS.111.967208.
- Walsh M, Fritz S, Hake D, Son M, Greve S, Jbara M, Chitta S, Fritz B, Miller A, K Bader M, et al. Targeted thromboelastographic (TEG) blood component and pharmacologic hemostatic therapy in traumatic and acquired coagulopathy. Curr Drug Targets 2016;17:954–970. doi:https://doi.org/10.2174/1389450117666160310153211.
- Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005;3:2039–2043. doi:https://doi.org/10.1111/j.1538-7836.2005.01513.x.
- Denmark KT, Bax JJ, Morrow DA, Task A, Members F, Kristian C, Denmark T, White HD, Zealand N, Denmark HM, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2018;00:1–33. doi:https://doi.org/10.1093/eurheartj/ehy462.
- Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, et al. NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018;71:177–192. doi:https://doi.org/10.1016/j.jacc.2017.11.014.
- Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Use of lipoprotein(a) in clinical practice: A biomarker whose time has come—A scientific statement from the National Lipid Association. J Clin Lipidol 2019:13:374-392. doi: https://doi.org/10.1016/j.jacl.2019.04.010.
- Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, Antonino MJ, Tantry US, Cohen E. Adenosine diphosphate-induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010;160:346–354. doi:https://doi.org/10.1016/j.ahj.2010.05.034.
- Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SLT, Braunwald E, Wiviott SD, Cohen DJ, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155–2166. doi:https://doi.org/10.1056/NEJMoa1409312.
- Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN, Lee DP, Steg PG, Weaver WD, Holmes DR, et al. Diabetes mellitus and prevention of late myocardial infarction after coronary stenting in the randomized dual antiplatelet therapy study. Circulation 2016;133:1772–1782. doi:https://doi.org/10.1161/CIRCULATIONAHA.115.016783.
- Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 1993;32:4628–4633. doi:https://doi.org/10.1021/bi00068a021.
- Berger M, Wraith K, Woodward C, Aburima A, Raslan Z, Hindle MS, Moellmann J, Febbraio M, Naseem KM. Dyslipidemia-associated atherogenic oxidized lipids induce platelet hyperactivity through phospholipase Cγ2-dependent reactive oxygen species generation. Platelets 2019;30:467–472. doi:https://doi.org/10.1080/09537104.2018.1466386.
- Wang X, Fu YF, Liu X, Feng G, Xiong D, Mu GF, Chen FP. ROS Promote ox-LDL-induced platelet activation by up-regulating autophagy through the inhibition of the PI3K/AKT/mTOR pathway. Cell Physiol Biochem 2018;50:1779–1793. doi:https://doi.org/10.1159/000494795.
- Barre DE. Lipoprotein (a) reduces platelet aggregation via apo(a)-mediated decreases in thromboxane A2 production. Platelets 1998;9:93–96. doi:https://doi.org/10.1080/09537109876852.
- Rodondi NMD, MAS, Ms, den Elzen WPJ MSc, Bauer DC MD, Cappola AR MD, ScM, Razvi S MD, FRCP, Walsh JP MBBS, FRACP, PhD, Åsvold BO MD, PhD, Iervasi G MD, Imaizumi P M. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein (a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009;203:371–376. doi:https://doi.org/10.1016/j.atherosclerosis.2008.07.019.
- Bowbrick VA, Mikhailidis DP, Stansby G. Influence of platelet count and activity on thromboelastography parameters. Platelets 2003;14:219–224. doi:https://doi.org/10.1080/0953710031000118849.
- Oshita K, Az-ma T, Osawa Y, Yuge O. Quantitative measurement of thromboelastography as a function of platelet count. Anesth Analg 1999;89:296–299. doi:https://doi.org/10.1097/00000539-199908000-00006.
- Kameda S, Sakata T, Kokubo Y, Mitsuguro M, Okamoto A, Sano M, Miyata T. Association of platelet aggregation with lipid levels in the Japanese population: the suita study. J Atheroscler Thromb 2011;18:560–567. doi:https://doi.org/10.5551/jat.6288.
- Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res 2016;57:1953–1975. doi:https://doi.org/10.1194/jlr.R071233.
- Waldeyer C, Makarova N, Zeller T, Schnabel RB, Brunner FJ, Jørgensen T, Linneberg A, Niiranen T, Salomaa V, Jousilahti P, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J 2017;38:2490–2498. doi:https://doi.org/10.1093/eurheartj/ehx166.
- Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: A mendelian randomization analysis. JAMA Cardiol 2018;3:619–627. doi:https://doi.org/10.1001/jamacardio.2018.1470.
- Ooi EM, Ellis KL, Barrett PHR, Watts GF, Hung J, Beilby JP, Thompson PL, Stobie P, McQuillan BM. Lipoprotein(a) and apolipoprotein(a) isoform size: associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque. Atherosclerosis 2018;275:232–238. doi:https://doi.org/10.1016/j.atherosclerosis.2018.06.863.
- Sun D, Zhao X, Li S, Zhang Y, Wu NQ, Zhu CG, Guo YL, Gao Y, Qing P, Liu G, et al. Lipoprotein(a)as a marker for predicting the presence and severity of coronary artery disease in untreated Chinese patients undergoing coronary angiography. Biomed Environ Sci 2018;31:253–260. doi:https://doi.org/10.3967/bes2018.033.
- Málek F, Dvořák J, Skalníková V, Mates M, Kmoníček P, Vávrová Z, Neužil P. Correlation of lipoprotein(a) with the extent of coronary artery disease in patients with established coronary atherosclerosis: gender differences. Eur J Prev Cardiol 2015;22:603–605. doi:https://doi.org/10.1177/2047487314527849.